Nottingham, UK-based Sygnature Discovery has expanded its drug metabolism and pharmacokinetics (DMPK) team with the appointment of Dr Edward Browne as associate director.
Dr Browne (pictured right) moves to the drug discovery service provider from GlaxoSmithKline, where he most recently served as head of DMPK for its Singapore operations.
He first joined GSK as a bioanalytical scientist in 2000, before working at Simbec Research in a similar post.
In 2005, Dr Browne re-joined GSK, becoming a team leader in its neural pathways discovery performance unit in Singapore before taking on increasingly senior roles.
Dr Timothy Schulz-Utermoehl, director of DMPK at Sygnature Discovery, said: “I am delighted to welcome Ed to the team here at Sygnature.
“Ed brings significant DMPK and drug discovery experience to our rapidly expanding department as we continue to build our CNS expertise and large molecule bio analysis.”